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Abstract
Background and objectives: Mullerian adenosarcoma is an uncommon variant of mixed mesodermal tumour of the uterus. This is a 
case report of a 65 year old post-menopausal lady who presented with complaints of passing tissue fragments per vaginum for 2 days 
followed by spotting. On examination, a polypoid mass protruding through the cervix was seen which was biopsied. Following a 
  preliminary histologic diagnosis of poorly differentiated sarcoma on the biopsy; the patient underwent total abdominal hysterectomy 
with bilateral salpingo-oopherectomy.
Method: The surgical specimen was formalin fixed and paraffin embedded. Haematoxylin and eosin stained sections were studied.
Result and conclusion: Histopathological examination of the polypoid mass revealed a tumour comprising of an admixture of benign 
endometrial glandular component with overgrowth of sarcomatous stromal component and heterologous elements. This may pose a 
problem in diagnosis due to its rarity, and hence its distinctive morphological features merit attention as described here. In view of the 
rarity of this tumor, it is mandatory to do extensive histologic sampling to identify areas of sarcomatous overgrowth before arriving at 
a diagnosis of mullerian adenosarcoma as the clinical course and management vary.
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Introduction
A 65 year old lady, postmenopausal for more than 
20  yrs  presented  to  the  gynaecology  department 
with  complaints  of  severe  back  pain  for  1  month 
before which she was symptom free. She presented 
with a history of fever for 4 days and passing tissue 
  fragments per vagina during micturition for 2 days 
followed by spotting. She had no history of previous 
surgery or radiotherapy. General physical examina-
tion  was  unremarkable.  Per  vaginal  examination 
revealed a large polypoid mass protruding through 
the  cervix  non  separable  from  the  uterus.  Routine 
  laboratory  tests  were  within  normal  limits  except 
for an increase in fasting and post -prandial blood 
sugar levels. A biopsy from the protruding polypoid 
mass was reported as poorly differentiated sarcoma, 
  following which a total abdominal hysterectomy with 
bilateral  salpingo-oopherectomy  was  done  and  the 
specimen sent for histopathological examination.
Method
The surgical specimen was formalin fixed and par-
affin embedded. Gross examination of hysterectomy 
specimen  with  bilateral  adnexa  weighed  180  gm, 
sectioning  revealed  a  polypoid  mass  measuring 
7 × 6 × 4.5 cm arising from the posterior wall of 
uterine corpus   distending the uterine cavity and pro-
truding through the cervix (Fig 1). On sectioning the 
polypoid mass was firm grey- white, haemorrhagic 
with  glistening/myxoid  areas  and  foci  of  necrosis. 
The myometrium showed invasion upto 1 cm. The left 
uterine wall showed an intramural fibroid (,1 cm) 
with a firm whorled white cut surface. The cervix and 
bilateral adnexa appeared unremarkable. Haematoxy-
lin and eosin stained sections were studied. For light 
microscopy, representative blocks embedded in par-
affin were cut at 6 micron thickness.
Result
Histopathological examination of the polypoid mass 
revealed  a  tumour  with  a  predominantly  stromal 
  component  (comprising  more  than  25%  of  the 
tumour) which was frankly sarcomatous composed of 
fascicles of poorly differentiated spindle shaped cells 
  exhibiting mild to moderate nuclear atypia (Fig 2). 
Brisk mitosis, tumour giant cells and heterologous 
elements  represented  by  rhabdomyosarcomatous 
  differentiation were seen. (Fig 3) Extensive sampling 
revealed  focal  benign  to  atypical  glands  including 
occasional cystically dilated glands.
Discussion
Mullerian adenosarcoma is a rare malignant tumour 
of  the  uterus  that  was  described  by  Clement  and 
  Scully.1  Majority  of  adenosarcomas,  including  the 
current case, occur in post menopausal women. These 
tumours can present as a pelvic mass (37%), uterine 
polyp  (22%)  as  in  our  case  or  an  enlarged  uterus 
(22%).2 Risk   factors that have been   associated with 
an  increased  risk  of  uterine  adenosarcoma  include 
  unopposed estrogen stimulation,3 long term oral con-
traceptive pills4 and prolonged use of   Tamoxifen5,6 for 
breast carcinoma. Our patient had none of these risk 
factors. They are usually of low malignant   potential. 
Few  of  these  tumours  are  clinically    malignant, 
since  many  of  them  pursue  an  indolent  course. 
Zaloudek  et  al7  noted  that  the  only  morphological 
feature   associated with increased risk of recurrence 
or    metastasis  is  the  presence  of  deep  myometrial 
  invasion.  Mullerian  adenosarcoma  is  characterized 
Figure 1. Gross photograph of the specimen showing a polypoid tumour 
arising  from  the  uterine  corpus  and  protruding  through  the  os  with 
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by an intimate   admixture of benign but   occasionally 
atypical    endometrial  glands  and  a  sarcomatous, 
  usually low grade stromal component. These glands 
may  be  lined  by  proliferative    endometrioid  (as  in 
this case), endocervical, squamous, serous or secre-
tory endometrioid cells and are surrounded by the 
  sarcomatous  component. The  stromal  cellularity  is 
more around the glands resulting in the formation 
of “periglandular cuffs”.   However this feature was 
not seen in our case. The stroma can be endometrial 
stromal sarcoma alone, fibrosarcoma alone or a mix-
ture of the two. Further, stromal secondary changes 
including   fibrosis and variable   hyalinization may also 
be  seen.  In    addition,  foci  of  edema,  haemorrhage, 
inflammation  and  myxoid  change  may  be  present. 
The term   “Mullerian adenosarcoma with   sarcomatous 
overgrowth (MASO) was first used by Clemant and 
Scully8 in 1989 for those tumours in which a pure 
  sarcoma, similar to or of a higher grade than that of 
the  underlying  adenosarcoma  accounts  for  atleast 
one-quarter of the tumour after thorough histologi-
cal sampling. Seidman et al9 in their study have noted 
that tumours with sarcomatous overgrowth occurred 
in younger women, were larger and were more likely 
to  have  heterologous  elements  as  compared  with 
those without sarcomatous overgrowth. The main dif-
ferential diagnosis of MASO is typical adenosarcoma 
with stromal predominant areas. Hence, Clement rec-
ommends that the diagnosis of MASO be rendered 
only when a pure sarcoma accounts for atleast one 
fourth of the tumour after thorough histological sam-
pling of the hysterectomy specimen. Correct classi-
fication of MASO is important because the limited 
available data suggest that the prognosis is notably 
worse than that for adenosarcomas without sarcoma-
tous overgrowth.10
The  management  of  patient  with  MASO  is 
  similar to that of a highly malignant uterine   sarcoma. 
Total  abdominal  hysterectomy  with  bilateral 
  salpingo-oopherectomy  can  be  curative  if  disease 
is confined to the uterus with a five year survival 
approximately 50%.11 Adjuvant radiotherapy appears 
to have a role in better pelvic control and decrease in 
local   recurrence of the tumor.12 Data regarding adju-
vant chemotherapy is very controversial,   especially 
with the paucity of studies and lack of control. Patients 
with MASO should therefore receive long-term post-
operative surveillance in view of the likelihood of late 
  recurrence. No pattern of difference in recurrence or 
survival has been documented between homologous 
or   heterologous elements.
conclusion
We  feel  that  due  to  the  rarity  of  this  tumor,  it  is 
  mandatory  to  do  extensive  histologic  sampling  to 
identify  areas  of  sarcomatous  overgrowth  before 
arriving at a diagnosis of mullerian adenosarcoma as 
the clinical course and management vary.
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